We have previously characterized the prognostic value of TROP2 in a cohort of 58 Epstein-Barr virus (EBV) associated nasopharyngeal carcinoma (NPC) and demonstrated that TROP2 was an independent predictor for poor clinical outcome 11. This evidence concerns the gene TACSTD2 and nasopharyngeal carcinoma.